Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

8.300 +0.300 (+3.75%)
Streaming Delayed Price Updated: 9:37 AM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Oric Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Top movers analysis one hour before the close of the markets on 2026-04-01: top gainers and losers in today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
News headline image
What's Behind The Drop In Oric Pharmaceuticals Stock Today? ↗
Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients... 
Via Benzinga
These stocks are gapping in today's session ↗
Via Chartmill
Which stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships. 
Via The Motley Fool
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading... 
Via Benzinga
Topics Stocks
News headline image
This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
ORIC Pharmaceuticals Inc (NASDAQ:ORIC) Reports Q2 2025 Wider Loss but Extends Cash Runway with Strategic Restructuring ↗
ORIC Pharmaceuticals reports Q2 2025 results with a wider loss but extends cash runway to 2H 2028. Updates on ORIC-944 and enozertinib show progress in oncology trials. 
Via Chartmill
News headline image
Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial ↗
The company also announced a $125 million private placement to fund its upcoming Phase 3 trial for ORIC-944 in metastatic prostate cancer. 
Via Stocktwits
News headline image
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results ↗
 
Via Benzinga
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital ↗
ORIC's Phase 1b trial of ORIC-944 in mCRPC shows PSA responses and strong tolerability, with Phase 3 trials and financing plans underway. 
Via Benzinga
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Veeva Systems, e.l.f. Beauty, C3.ai, BRP And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Wednesday's after-hours session. ↗
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Tuesday's session: gap up and gap down stocks ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
H&E Equipment Services, ACM Research, Robinhood And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about. 
Via MarketBeat
News headline image
ORIC Stock Earnings: ORIC Pharmaceuticals Misses EPS for Q2 2024 ↗
ORIC stock results show that ORIC Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
ORIC Stock Earnings: ORIC Pharmaceuticals Beats EPS for Q1 2024 ↗
ORIC stock results show that ORIC Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.